



FOR IMMEDIATE RELEASE

**Silicon Kinetics Wins 2009 "R&D 100 Award"
For Dual-Format Biomolecular Interaction Analysis Platform**

San Diego, California, July 29, 2009 -- SKi Pro™ biomolecular interaction analysis platform by Silicon Kinetics Inc., a privately-held life sciences tool company, has been awarded the R&D 100 Award in the Bioscience category by R&D Magazine in its 47th annual awards.

Silicon Kinetics SKi Pro is the world's first dual-format, label-free platform for biomolecular interaction analysis in proteomics research, biomarker and drug discovery, vaccine development as well as quality control in drug manufacturing. SKi Pro instruments read a unique 3D nano-porous silicon biosensor surface, either in a multi-well plate reader or flow-cell format, for high sensitivity measurement of interactions such as protein-protein, DNA-protein, protein-small molecule. In addition, SKi Pro offers 500-fold efficiency improvement versus traditional methods in affinity capture for mass spec analysis, an application called AC-MS.

"SKi Pro provides unique benefits in performance and workflow to researchers in pharmaceutical and biotech industries, and in research and academic institutions," said Hus Tigli, President and CEO of Silicon Kinetics. "These benefits come from a combination of innovative technologies, as recognized by our customers, and now by the R&D 100 Award."

Last December, the Company had been selected as the 2008 winner in the Research and Diagnostics Tools category of the 21st Annual Most Innovative New Product (MIP) Awards by CONNECT, a non-profit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego, California.

About Silicon Kinetics

Silicon Kinetics, Inc. is a privately-held life sciences tools company headquartered in San Diego, California. The Company specializes in instruments for optical interferometry in nano-porous silicon biochips. The SKi Pro™ instrument platform and the 3D SKi Sensor™ biochips are used to detect protein-protein, protein-drug, or protein-DNA interactions in real-time and quantify binding kinetics, dissociation rates, or biomolecular affinity rankings, required for the study of disease pathways and the development and manufacturing of therapeutics. More information can be found at <http://www.siliconkinetics.com>.

###

Media contacts:

Ronald P. Dudek
Director, Market Development
(517) 294-7272
rdudek@siliconkinetics.com

Cynthia Guiang
CG Communications
(858) 793-2471
cynthia@cgcommunications.com